Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety of FSME-IMMUN NEW vs Encepur in Healthy Adults
NCT00161824Phase 3Completed
- Sponsor
- Pfizer
- Start
- Oct 2001
- Modality
- Whole Inactivated Vaccines
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial of FSME-IMMUN in tick-borne encephalitis (TBE) (2 arms), sponsored by Pfizer. Primary endpoint: Safety and Tolerability of Two Vaccinations. Started Oct 2001; status: completed.
02
Drugs
FSME-IMMUN
03
Conditions
tick-borne encephalitis (TBE)
Beyond the preview
Go deeper on NCT00161824.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00161824.